Medera’s Novoheart Partners with AstraZeneca on First Bioengineered Human Models of Heart Failure

Medera Biopharmaceutical and Novoheart, together with AstraZeneca, are delighted to announce that their ongoing collaboration has led to the successful development of the world’s first human-specific in vitro, functional models of heart failure with preserved ejection fraction (HFpEF).